ELOVL6 promotes the progression of head and neck squamous cell carcinoma via activating WNT/β‐catenin pathway
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23710 ↗At a glance
Journal article in Molecular Carcinogenesis, 2024. Written by Ruoya Wang and 10 co-authors. Institution: Department of Otolaryngology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China. Major MEDLINE topics: Fatty Acid Elongases, Gene Expression Regulation, Neoplastic, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck. Cited 7 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY 4.0). Funded by: Guiding Science and Technology of Jinzhou, Horizontal Research Project of Jinzhou Medical University.
Abstract (original language)
This study was to explore the role of ELOVL6 in the development of head and neck squamous cell carcinoma (HNSCC). Considering its previously identified oncogenic role in hepatocellular carcinoma. ELOVL6 gene expression, clinicopathological analysis, enrichment analysis, and immune infiltration analysis were based on the data from Gene Expression Omnibus and The Cancer Genome Atlas, with additional bioinformatics analyses performed. Human HNSCC tissue microarray and cell lines were used. The expression of ELOVL6 in HNSCC was detected by quantitative polymerase chain reaction, immunohistochemistry assay, and western blot analysis. The proliferation ability of HNSCC cells, invasion, and apoptosis were evaluated using cell counting kit‐8 method, Transwell assay, and flow cytometry, respectively. Based on the data derived from the cancer databases and our HNSCC cell and tissue studies, we found that ELOVL6 was overexpressed in HNSCC. Moreover, ELOVL6 expression level had a positive correlation with clinicopathology of HNSCC. Gene set enrichment analysis showed that ELOVL6 affected the occurrence of HNSCC through WNT signaling pathway. Functional experiments demonstrated that ELOVL6 knockdown inhibited the proliferation and invasion of HNSCC cells while promoting apoptosis. Additionally, compound 3f, an agonist of WNT/β‐catenin signaling pathway, enhances the effect of ELOVL6 on the progression of HNSCC cells. ELOVL6 is upregulated in HNSCC and promotes the development of HNSCC cells by inducing WNT/β‐catenin signaling pathway. ELOVL6 stands a potential target for the treatment of HNSCC and a prognosis indicator of human HNSCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Otolaryngology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
- Department of Radiology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Funding
- Guiding Science and Technology of Jinzhou
- Horizontal Research Project of Jinzhou Medical University
Cite
APA
Wang, R., Liu, X., Li, X., Qian, M., Yang, X., Jiang, Q., Wang, Y., Liu, H., Chen, J., Wang, X., & Gong, L. (2024). ELOVL6 promotes the progression of head and neck squamous cell carcinoma via activating WNT/β‐catenin pathway. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23710
Vancouver
Wang R, Liu X, Li X, Qian M, Yang X, Jiang Q, et al. ELOVL6 promotes the progression of head and neck squamous cell carcinoma via activating WNT/β‐catenin pathway. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23710
BibTeX
@article{Wang2024,
author = {Wang, Ruoya and Liu, Xianzhi and Li, Xiyao and Qian, Ming and Yang, Xi and Jiang, Qichuan and Wang, Yijie and Liu, Hao and Chen, Jianguo and Wang, Xuefeng and Gong, Liang},
title = {ELOVL6 promotes the progression of head and neck squamous cell carcinoma via activating WNT/β‐catenin pathway},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23710}
}
EUVIMED